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e novo variants are considered strong supporting evidence of pathogenicity in the most recent genetic classification guidelines presented by the American College of Medical Genetics and Genomics. 1 The distinction between monogenetic de novo variants and benign recurrent variation or standing variation in the general population has been difficult because of the inadequate size of available reference population datasets. For this reason, many de novo variants may have been misclassified as disease causing. Recent studies have questioned several variants previously associated with cardiac disease in the general population [2] [3] [4] [5] and highlighted the importance of using large population cohorts when studying genetics of a disease. For example, Kosmicki et al 6 showed that many de novo variants previously linked with neurodevelopment disorders are observed as standing variation in the general population and further demonstrated that these recurring variants do not contribute significantly to increased risk for disease. Considering these findings, it is important to investigate the minor allele frequency of de novo variants in cardiac disease. The reference population in the Exome Aggregation Consortium (ExAC) database, 7 consisting of exome data from 60 706 individuals without severe developmental disorders, has been of great significance in this work. The database can be considered representative of the general population and is as such useful for analyses of rare variants involved in diseases.
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Trio studies, which strictly refer to inclusion of data from case and parents, have given an important insight into the pathogenicity of various diseases: for example, congenital heart disease (CHD), [8] [9] [10] cardiac arrhythmias, 11, 12 and cardiomyopathies. 13, 14 Large CHD trio studies (>1000 subjects) [8] [9] [10] have resulted in the identification of thousands of de novo variants associated with both cardiac and noncardiac traits. Zaidi et al 8 
estimated that the identified de novo variants De Novo Variants and Heart
cause ≈10% of severe CHD. Similarly, in a study by Homsy et al, 9 the authors showed that damaging variants in highly heart expressed (HHE) genes contribute to ≈20% of syndromic CHD and ≈2% of isolated CHD (absence of extracardiac congenital abnormalities and neurodevelopment disabilities).
We aim to investigate whether de novo variants previously associated with cardiac disease can be identified in the reference population ExAC, in numbers greater than the expected prevalence for the questioned diseases.
Methods
Readers will be able to reproduce the findings because methods and study materials are presented in the following sections and in the Data Supplement. The data are accessible in online public databases; hence the project did not need ethical approval.
Search Query
We searched for de novo variants associated with severe cardiac arrhythmias and structural cardiac diseases in PubMed with the following search queries: Brugada syndrome (MeSH) or Brugada, ventricular tachycardia (MeSH), ventricular fibrillation (MeSH), polymorphic ventricular tachycardia (MeSH), catecholaminergic polymorphic ventricular tachycardia (MeSH) or CPVT, long QT syndrome (MeSH) or long QT or LQTS or LQT, Torsades de pointes (MeSH), short QT syndrome (MeSH) or short QT or SQTS or SQT, sudden cardiac death (MeSH) or SCD or sudden cardiac arrest (MeSH), hypertrophic cardiomyopathy (MeSH) or HCM, dilated cardiomyopathy (MeSH) or DCM, arrhythmogenic right ventricular dysplasia (MeSH) or ARVD, arrhythmogenic right ventricular cardiomyopathy or ARVC, sudden infant death syndrome (MeSH) or SIDS (MeSH), congenital heart disease (MeSH) or congenital heart defect (MeSH) or CHD, left ventricular noncompaction or LVNC, and monogenic or genetics (MeSH) or genetic or trio or TRIOS, and de novo. The search resulted in 396 articles (March 2017). The publications were examined for information regarding de novo occurrence, functional data, and clinical data.
Rationale for Variant Inclusion and Categorization
The query result spanned from single-case reports to studies with >1000 trios and could be divided into 2 main groups. The first group, denoted group A, consists of studies that define their findings as monogenic cause and includes different cardiac phenotypes. The second group, denoted group B, contains studies that explored the burden of de novo variation between cases and controls only in CHDs. Our rationale for inclusion and exclusion of variants and then categorization of variants is shown in Figure 1 . The distinction between the 2 groups could primarily be based on the number of subjects included in the studies. Most single-case reports and smaller trio studies (≤200 subjects) considered their de novo variants monogenic. We excluded variants in studies where the cardiac phenotype could not be properly confirmed and variants that were reported in combination with other variants (nonmonogenic). Last, 1 mitochondrial variant was not included. The larger trio studies (>1000 subjects) considered their findings as contributors to disease, and all variants from these studies were included.
In group A, we identified de novo variants associated with isolated CHD (no other congenital abnormalities) and variants where CHD was a secondary finding to other congenital diseases with no specific syndromes. These are categorized together under CHD (Table 1; Table I in the Data Supplement). Some cardiac diseases, especially CHD, are related to different syndromes. Therefore, variants in syndromic probands presenting cardiac disease are included and categorized under their respective syndromes in Table 1 and Table I in the Data Supplement. For better demonstration, we present the variants based on their type of cardiac disease in Figure 2B . When interrogating the variants, we do it according to the prevalence of the respective cardiac phenotypes (Table 2) . Figure 2B and Table 2 . If a proband presented several cardiac diseases (eg, CHD and cardiomyopathy), the phenotype considered primary was used for categorization. Phenotypes related to severe chromosomal configurations, such as trisomies, translocations, larger insertions, larger deletions, and larger duplications, were excluded.
Reference Database
De novo variants identified in the study were queried in the ExAC database. ExAC represents a diverse population containing 60 706 unrelated individuals (121 412 alleles at each locus in the genome), which is compiled of various disease-specific and population genetic studies, using different platforms (mostly Agilent, Illumina, NimbleGen, and a minority of others). Participants with severe pediatric diseases have been removed from the database, and data have previously been shown to be eligible as a reference for allele frequencies when studying severe genetic diseases. 7, 36, 37 Furthermore, ExAC is not enriched for the cardiac diseases questioned in this study and is considered to be representative of the general population. Variants located in introns and untranslated regions cannot be identified in ExAC, and, therefore, only exonic regions are included. 7 ExAC does not provide phenotypic data, thus we must evaluate the variants based on the theoretically expected number of affected individuals in the database De novo variants that are observed as standing variation, and recurrent variation in ExAC are referred to as class 2 de novo variants and otherwise as class 1 de novo variants.
Statistical Analysis
We calculated the expected number of affected subjects in ExAC (by any of the investigated diseases) by using previously reported prevalence estimates. 27, 29, 31, 32, 34, 38 Furthermore, we assumed that there was no overlap between the phenotypes. To demonstrate that class 2 de novo variants are unlikely to be monogenetic, we calculated the proportion of disease prevalence that could be explained by class 2 variation, if these were truly monogenetic.
The proportion of a disease in ExAC explained solely by recurrent variants at the sites of the identified class 2 de novo variants was estimated using the equation depicted below.
Hypothetical proportion of the disease explained by variation corresponds to that at the sites of the class 2 variants. Total allele count refers to that in ExAC at the sites for class 2 variants of a given disease, and u is the estimated number of individuals affected by the disease in ExAC based on the disease prevalence. The upper and lower 95% confidence intervals were calculated using a binominal distribution.
Expected Recurrence Count
We calculated the expected recurrence count depending on the size of the reference population using a hypergeometric distribution. 6 Expected count r
Where r is a set of alleles with the allele count K, N refers to the allele number in the reference database (≈the allele number in ExAC, which is 121 412), and n corresponds to the subset size.
Results
The search query identified single-case reports and smaller (n≤200) and larger (n>1000) trio studies from a total of 396 publications. The single-case reports and smaller trio studies, denoted group A, report relative few monogenic de novo variants in specific cases, whereas the larger trio studies, denoted group B, report thousands of proposed susceptibility de novo variants in almost as many genes. Group A contains studies that examined different cardiac phenotypes, whereas studies in group B solely investigated CHD.
Variants Reported in Case Reports and Smaller Trio Studies
In group A, we identified 211 de novo variants previously associated with severe cardiac arrhythmias, cardiomyopathies, and CHD in various genes (Table I in the Data Supplement). These variants have been implicated with monogenic cause of disease. The most important phenotypes included CHD, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and ion channel traits, such as Brugada syndrome (BrS), long QT syndrome, and catecholaminergic polymorphic ventricular tachycardia.
Using the ExAC database, which is assumed to represent the general population, 11% (23/211) of the de novo variants were categorized as class 2 variants (19 missense variants and 4 nonsense variants; Figure 2A ). These variants have been associated with 10 different phenotypes ( Table 1 ). The variants are categorized according to the overall phenotype in Table 1 and Table I in the Data Supplement, whereas we present the variants ordered by their type of heart disease in Figure 2B ( Figure 1 ). The variants are interrogated using a theoretically estimated allele count, which is based on the prevalence of the respective cardiac phenotypes in Table 2 .
Because the prevalence of left ventricular noncompaction is not properly estimated and CASQ2-caused catecholaminergic polymorphic ventricular tachycardia is recessive inherited, we did not include these 2 variants (TNNT2 R131W and CASQ2 P308L) in the further analyses. The total allele count in ExAC at class 2 sites was 109 in ≈844 theoretically expected cases, which if assuming an autosomal dominant effect hypothetically would explain 13% of the disease burden in the investigated diseases, solely by attributing the 21 previously reported sites a highly penetrant monogenetic status (Table 2) . BrS had the highest recurrence rate (50%), and by assuming these sites are monogenetic, 155% (47/30) of Brugada cases in ExAC would be caused by the variation at these 4 sites only. De novo variants identified as causing CHD had a recurrence Figure 1 . The flowchart demonstrates our rationale for grouping the variants in groups A and B (black). Hereafter, the rationale for categorization of variants based on phenotypes in Table 1 and Table I in the Data Supplement (blue), and last, the grouping of variants based on type of cardiac disease and cardiac phenotype for presentation in Figure 2B (green) and interrogation in Table 2 (red), respectively. CHD indicates congenital heart disease. Table 2 .
Variants Reported in Larger Trio Studies
Group B includes 3 larger trio studies (n>1000), which investigated CHD. [8] [9] [10] We have included all variants from the CHD cases in the work published by Zaidi et al, 8 Homsy et al, 9 and Sifrim et al. 10 Proportions of data in these studies originate from the same data set; hence we have excluded duplicates. The present analysis includes 3050 unique de novo variants across 2537 genes reported in group B (Table II in the Data Supplement).
In the ExAC database, we identified 26% (802/3050) de novo variants in 748 genes previously found in CHD cases ( Figure 3 ; Table III in the Data Supplement). In the original studies, the variants were considered either as risk variants for cardiac disease or as innocent bystanders. Zaidi et al 8 considered the identified de novo variants to be responsible for ≈10% of severe CHD. Therefore, the authors in the original publication have focused on specific variants that they have concluded to be of interest and categorized the variants based on their expression in heart tissue. We studied variants in HHE genes, which were divided as damaging mutations, silent mutations, variants at conserved positions, and variants at nonconserved positions (Tables II and III in the Data Supplement) . Of the 15 damaging de novo variants in HHE genes, none were present in ExAC, supporting the evidence of their pathogenicity. However, in the remaining HHE genes, the recurrence rate was 23% (9/39) at conserved positions, 30% (8/27) at nonconserved positions, and 43% (9/21) for silent variants. In total, 25% (26/102) de novo variants in HHE genes were identified in ExAC. Additionally, the authors specified a list with genes of interest, which focused on chromatin-modifying genes presenting 28 variants in 26 genes. From this list, we have identified 18% (5/28) as class 2 de novo variants. The disease and estimated prevalence of disease are in the first and second columns. The variant recurrence rate for each disease and number of class 1 and 2 variants identified are laid out in the third column. Collective allele counts in ExAC for class 2 variants in each disease are in the fourth column. The fifth column presents the estimated number of subjects for the respective diseases in ExAC with 95% CI, given the prevalence of the diseases. The sixth column shows the HEV at the sites of the class 2 variants for each phenotype based on estimated penetrance. The last column presents HEV with 95% CI, if class 2 variants are assumed to be monogenetic. AC indicates allele count; ARVC, arrhythmogenic right ventricular cardiomyopathy; BrS, Brugada syndrome; CHD, congenital heart disease; CI, confidence interval; DCM, dilated cardiomyopathy; ExAC, Exome Aggregation Consortium; HCM, hypertrophic cardiomyopathy; HEV, hypothetical proportion of the disease explained by variation; LQTS, long QT syndrome; and NA, not available. The recurrence of variants will depend on the size of the reference population. Based on the recurrence in ExAC, we estimate the expected number of class 2 CHD-associated variants in group B depending on different reference sizes (Figure 4) . Most commonly used reference sets before ExAC release were the 1000 Genomes Project (n=2504) and the Exome Sequencing Project (n=6500). Larger reference samples greatly increase the amount of class 2 variants as illustrated with the expected recurrence rate of 5% in 1000 Genomes Project, 9% in Exome Sequencing Project, and 26% in ExAC ( Figure 5 ).
Discussion
De novo variants implicated with a disease are often assumed to be private variations and strongly pathogenic. If the exclusivity of de novo variants is questioned, so is their pathogenicity. Previous studies have varied from single trio case reports to larger trio studies with >1000 probands. The approach and conclusions from these studies have been different, and we, therefore, divide our findings into groups A and B. The studies in group B provide quantitative evidence of disease causality compared with group A; hence the groups are analyzed differently. Specific variants are interrogated in group A, whereas the recurrence of de novo variants is described in group B.
The studies in group A have revealed 211 variants believed to be de novo and monogenic cause of different cardiac diseases, of which 11% (23/211) were identified as standing variation in the large exome database ExAC. We show that previously reported de novo variants are present in the general population, which challenges their pathogenicity and clinical relevance. We show that a dubiously large proportion of various heart diseases, for example, CHD, dilated cardiomyopathy, long QT syndrome, and BrS, would be attributed solely to 21 sites in the exome, if class 2 de novo variants were truly monogenetic (13% [109/844] of burden in investigated diseases; Table 2 ). The recurrence rate of BrS (50%) stands out where 155% of all cases in ExAC would be explained by 4 sites, assuming an autosomal dominant effect. The overrepresentation of variants in the ExAC database could be a consequence of variants misclassified as highly penetrant pathogenic de novo variants because the database represents the general population and is not enriched for monogenic diseases. 7 The variants may be susceptibility variants that to some degree predispose to disease. Variants have been reported to have varying penetrance in different diseases 33 (Table 2 ). However, because these predictions are uncertain estimates, they can probably not be compared with the penetrance of de novo variants, which traditionally has been considered to be higher; hence we have not taken penetrance into account in the overall calculations. Individuals carrying pathogenic de novo variants could in addition have other risk factors that increase the susceptibility of disease, for example, other genetic variations, alterations in sympathetic tone, and medication. Also, recent evidence suggests that individuals harboring pathogenic variants could also carry protective variants, so called risk modifiers. 39, 40 These variants have an opposite effect on the phenotype, thus rescuing the deleterious effect of the initial variant.
Studies in group B focused on variants associated with CHD and identified 3050 de novo variants as potential disease contributors. We identified 26% (802/3050) de novo variants in the ExAC database. Kosmicki et al 6 have shown that recurrent de novo variation does not contribute significantly to the risk of neurodevelopmental disorders. Using a similar approach, it is reasonable to assume that this may be the case in cardiac disease as well. It is evident that larger reference samples greatly increase the identification of de novo variants. Figure 4 shows that the estimated number of class 2 variants in the smaller databases 1000 Genomes Project and Exome Sequencing Project would be ≈150 and ≈300, respectively, compared with ≈800 in ExAC, whereas the expected recurrence rate shown in Figure 5 would be 5%, 9%, and 26%, respectively. The expected recurrence of variants indicates that many of the evaluated de novo variants would likely not have been detected as class 2 when using smaller reference populations. This highlights the importance of using large reference populations as controls for evaluation of de novo variants.
Our findings question the monogenetic pathogenicity of some class 2 variants in group A, whereas variants in group B are only included to provide the full picture of recurrent variants identified in these important studies.
Variants associated with a range of different diseases have been identified in the general population, [2] [3] [4] [5] and recent findings have also challenged the concept of de novo variants. 6 Our study supports these findings and stresses the importance of carefully evaluating the pathogenicity of de novo variants before giving them a disease-causing status. This is of importance in a clinical setting where the use of genetic testing has increased during recent years. Caution is advised when genetic counseling is based on de novo variation, of which the pathogenicity is solely based on the frequency in the general population without supporting evidence, such as clinical tests and functional characterization.
Furthermore, by classifying a benign variant as pathogenic, the truly disease-causing variant could be bypassed. Studies have shown that variants listed in variant databases are frequently present in the general population. 2 This makes it more challenging to distinguish truly pathogenic variants from innocent bystanders because de novo variants may represent normal variation.
Variant frequency in combination with clinical data, family history, and preferably functional data should be included when classifying an identified variant. Incorrect diagnosis based on genetic testing may result in unnecessary medical consultations, irrelevant medical advice, and treatment, potentially leading to psychological and financial burden to patient, family, and society.
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Limitations
Individuals from the different publications studied in this work could theoretically be included in ExAC. However, because ExAC does not include severe pediatric disease and the identified consortia are not part of this collaboration, 7 the risk of this is considered small. Additionally, the same de novo variants can indeed occur in different individuals several times, 41 with specific hotspots being more susceptible to variation, 42 facilitating the possibility of those being more prevalent in the general population.
It is known that prevalence for various heart diseases varies between the sexes, for example, BrS and long QT syndrome being predominant in men and women, respectively. 43 However, the ExAC database does not provide sex information, and, therefore, it has not been possible to take sex differences into account when interrogating the previously reported variants.
Conclusion
We have identified many de novo variants previously considered monogenic cause in cardiac disease and >25% de novo variants previously assumed as potential risk contributors to cardiac disease in a large representative exome database. These results suggest that not all de novo variants are rare and contribute to risk. This is important in a clinical setting where a protein-altering de novo variant often routinely is considered the causal variant. Caution is, therefore, advised when incorporating de novo variants identified in the present work in genetic diagnosis because these might not be the monogenic cause of disease.
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